
Switzerland’s Actelion (SIX: ATLN), Europe’s largest biotech company, this morning posted a strong set of financial results for the first half of 2014, with product sales of 993 million Swiss francs ($1.03 billion), up 17% at constant exchange rates (CER), and up 11% excluding US rebate reversals.
Core operating income leapt 27% (35% at CER) to 421 million francs. US generally-accepted accounting principles (GAPP) earnings per share (fully diluted) rocketed 109% (124% at CER) to 3.62 francs and core EPS was up 39% (48% at CER) to 3.25 francs. Core earnings per share for the second quarter alone were 233 million francs, well ahead of the 171 million francs average forecast in a Reuters poll. Actelion’s shares rose 2.55% to 112.40 francs in early trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze